Cargando…

A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs

Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fanjin, Yu, Yang, Tian, Ye, Deng, Meng, Zheng, Kaiyuan, Guo, Xiaolan, Zeng, Beilei, Li, Jingjia, Qian, Airong, Yin, Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435887/
https://www.ncbi.nlm.nih.gov/pubmed/37600711
http://dx.doi.org/10.3389/fendo.2023.1219433
_version_ 1785092205948436480
author Meng, Fanjin
Yu, Yang
Tian, Ye
Deng, Meng
Zheng, Kaiyuan
Guo, Xiaolan
Zeng, Beilei
Li, Jingjia
Qian, Airong
Yin, Chong
author_facet Meng, Fanjin
Yu, Yang
Tian, Ye
Deng, Meng
Zheng, Kaiyuan
Guo, Xiaolan
Zeng, Beilei
Li, Jingjia
Qian, Airong
Yin, Chong
author_sort Meng, Fanjin
collection PubMed
description Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies on osteogenic LncRNAs, including sophisticated techniques, high cost for in vivo experiment, as well as low homology of LncRNAs between animal model and human, which hindered translational medicine research. Moreover, compared with gene editing, LncRNAs would only lead to inhibition of target genes rather than completely knocking them out. As the studies on osteogenic LncRNA gradually proceed, some of these problems have turned osteogenic LncRNA research studies into slump. This review described some new techniques and innovative ideas to address these problems. Although investigations on osteogenic LncRNAs still have obtacles to overcome, LncRNA will work as a promising therapeutic drug for osteoporosis in the near future.
format Online
Article
Text
id pubmed-10435887
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104358872023-08-19 A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs Meng, Fanjin Yu, Yang Tian, Ye Deng, Meng Zheng, Kaiyuan Guo, Xiaolan Zeng, Beilei Li, Jingjia Qian, Airong Yin, Chong Front Endocrinol (Lausanne) Endocrinology Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies on osteogenic LncRNAs, including sophisticated techniques, high cost for in vivo experiment, as well as low homology of LncRNAs between animal model and human, which hindered translational medicine research. Moreover, compared with gene editing, LncRNAs would only lead to inhibition of target genes rather than completely knocking them out. As the studies on osteogenic LncRNA gradually proceed, some of these problems have turned osteogenic LncRNA research studies into slump. This review described some new techniques and innovative ideas to address these problems. Although investigations on osteogenic LncRNAs still have obtacles to overcome, LncRNA will work as a promising therapeutic drug for osteoporosis in the near future. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435887/ /pubmed/37600711 http://dx.doi.org/10.3389/fendo.2023.1219433 Text en Copyright © 2023 Meng, Yu, Tian, Deng, Zheng, Guo, Zeng, Li, Qian and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Meng, Fanjin
Yu, Yang
Tian, Ye
Deng, Meng
Zheng, Kaiyuan
Guo, Xiaolan
Zeng, Beilei
Li, Jingjia
Qian, Airong
Yin, Chong
A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title_full A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title_fullStr A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title_full_unstemmed A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title_short A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
title_sort potential therapeutic drug for osteoporosis: prospect for osteogenic lncrnas
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435887/
https://www.ncbi.nlm.nih.gov/pubmed/37600711
http://dx.doi.org/10.3389/fendo.2023.1219433
work_keys_str_mv AT mengfanjin apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT yuyang apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT tianye apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT dengmeng apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT zhengkaiyuan apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT guoxiaolan apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT zengbeilei apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT lijingjia apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT qianairong apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT yinchong apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT mengfanjin potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT yuyang potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT tianye potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT dengmeng potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT zhengkaiyuan potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT guoxiaolan potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT zengbeilei potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT lijingjia potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT qianairong potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas
AT yinchong potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas